Which rifabutin patents are we talking about?
“Rifabutin” is a medicine (used for mycobacterial infections) that has multiple patents across different jurisdictions, and also across different “layers” such as the original active ingredient, specific manufacturing processes, and later formulation/combination IP. Patent status depends on the exact product (brand and country) and the specific patent family in force.
To answer precisely, you need at least one of:
- the country (e.g., US, EP, UK, India)
- the brand/product name the patent is tied to
- the patent number or application/publication number
- the holder/company name
Without that, the only accurate statement is that there isn’t a single, universal “rifabutin patent” covering the whole drug worldwide.
How long do rifabutin patents last (typical rules)?
Patent term generally runs from the filing date (often about 20 years), with possible extensions that vary by country and by whether patent term adjustments/extensions are available for pharmaceuticals. The practical “when can generics enter?” timeline can be earlier or later depending on:
- which patent in the family expires last (active ingredient vs. formulation vs. method of use)
- patent term adjustments/extensions granted by the regulator
- regulatory exclusivities that are separate from patents (country-specific)
When do generic rifabutin products typically become available?
Generic entry timing depends on the last-to-expire relevant patent(s) in the target market. In many cases, generics launch after patent expiry of the key claims, but launch can be delayed by:
- additional “secondary” patents (e.g., formulations, polymorphs, manufacturing)
- ongoing litigation/settlement terms (where applicable)
- regulatory exclusivity periods
If you tell me your country (and ideally the brand you care about), I can narrow to the likely patent landscape and what usually blocks or clears entry there.
Are there different patents for rifabutin formulations?
Yes. Even after the core substance patent expires, companies sometimes hold additional patents for things like:
- specific dosage forms or release characteristics
- manufacturing processes
- particular polymorphs or forms
- combination products or labeled uses (jurisdiction-specific)
Those “secondary” patents are often what complicate generic timelines.
What if you mean “patent” as in “who owns rifabutin right now”?
Ownership changes over time via mergers, assignments, and settlements. To identify the current assignee/owner, you need the specific patent document or the jurisdiction’s patent database record.
If you share the patent number, I can decode it
If you paste any of the following, I can help interpret the patent and its likely relevance to generic entry:
- a patent number (e.g., USxxxxxxx)
- a publication number (e.g., WOxxxxxxx)
- a link to a patent record
- the country + brand name
Quick next question (so the answer can be exact)
Which country’s rifabutin patent timeline do you want (US, EU, UK, India, etc.), and is there a brand/product name (or a patent number) you have in mind?